CORRECTION

Correction to: A Novel Bridging Strategy for Patients Undergoing Emergent Non-Cardiac Surgery with a Recent Coronary Stent

Cierra Bruck · Omar Jafar · Jayne Prats · Deepak Bhatt ·
Zubair Jafar

Published online: August 6, 2018
© The Author(s) 2018

Correction to: Cardiol Ther
<https://doi.org/10.1007/s40119-018-0113-2>

In the original publication, the abstract text, informed consent and disclosure text have been published incorrectly.

The text in the abstract section currently reads:

He was successfully fitted with a drug-eluting stent of the LAD, but subsequently developed a sarcoma 2 months later that required urgent surgery. The novel direct-acting, reversible P2Y₁₂ receptor inhibitor cangrelor was used to bridge this patient and ongoing antiplatelet treatment, allowing surgery for the removal of a soft tissue sarcoma.

The correct statement should read as:

He was successfully stented with a drug-eluting stent of the LAD, but subsequently developed a sarcoma 2 months later that required urgent

The original article can be found online at <https://doi.org/10.1007/s40119-018-0113-2>.

C. Bruck · O. Jafar · Z. Jafar (✉)
The Heart Center–Vassar Brothers Medical Center,
Poughkeepsie, NY, USA
e-mail: mjafar@health-quest.org

J. Prats
Elysis, LLC, Carlisle, MA, USA

D. Bhatt
Brigham and Women's Heart and Vascular Center,
Boston, MA, USA

surgery. The novel direct-acting, reversible P2Y₁₂ receptor inhibitor cangrelor was used to bridge this patient followed by ongoing antiplatelet treatment, allowing surgery for the removal of a soft tissue sarcoma.

Informed consent under the heading 'Case Information' currently reads:

Informed consent was obtained from all individual participants for inclusion in the study.

The correct statement should read as:

Informed consent was obtained from the individual participant for inclusion in the study.

The 'Disclosure' statement currently reads:

Dr. Jayne Prats is a former employee of The Medicines Company, previous sponsor of cangrelor; consultant to Chiesi-USA, who currently markets cangrelor. Ms. Cierra Bruck, Mr. Omar Jafar, Dr. Deepak Bhatt, and Dr. Zubair Jafar all have nothing to disclose.

The correct statement should read as:

Dr. Jayne Prats is a former employee of The Medicines Company, previous sponsor of cangrelor; consultant to Chiesi-USA, who currently markets cangrelor. Ms. Cierra Bruck, Mr. Omar Jafar and Dr. Zubair Jafar all have nothing to disclose. Dr. Deepak Bhatt discloses the following relationships—Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society

of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic, Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine, Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair);

Research Funding: Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi (including for his role as co-Chair of CHAMPION PHOENIX), Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, Phase-Bio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company (including for his role as co-Chair of the CHAMPION trials); Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, PLx Pharma, Takeda.

The original article has been corrected.

OPEN ACCESS

This article is distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.